Search

Your search keyword '"Katlinskaya, Yuliya"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Katlinskaya, Yuliya" Remove constraint Author: "Katlinskaya, Yuliya" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
28 results on '"Katlinskaya, Yuliya"'

Search Results

2. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

3. Supplementary Information from A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon

4. Spatial characterization and quantification of CD40 expression across cancer types

5. Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

6. Additional file 1 of Spatial characterization and quantification of CD40 expression across cancer types

7. Additional file 2 of Spatial characterization and quantification of CD40 expression across cancer types

8. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

9. Abstract P260: Development and validation of a novel T-cell modulating, microbiome-based peptide for combination with immunotherapy

10. Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

13. Abstract 4963: A novel intestinal microbiome-derived peptide modulates immune cell activity and the tumor microenvironment

15. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles

16. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

17. Abstract 1637: ICOS agonism induces potent immune activation and anti-tumor response in non-clinical models

18. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon

19. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment

20. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma

22. Type I Interferons Control Proliferation and Function of the Intestinal Epithelium

23. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression

25. DNA-Damage-Induced Type I Interferon Promotes Senescence and Inhibits Stem Cell Function

27. Type I Interferon Controls Propagation of Long Interspersed Element-1.

28. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer.

Catalog

Books, media, physical & digital resources